Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

Carlos Ferrando, Fernando Suarez-Sipmann, Ricard Mellado-Artigas, María Hernández, Alfredo Gea, Egoitz Arruti, César Aldecoa, Graciela Martínez-Pallí, Miguel A Martínez-González, Arthur S Slutsky, Jesús Villar, COVID-19 Spanish ICU Network

Abstract

Purpose: The main characteristics of mechanically ventilated ARDS patients affected with COVID-19, and the adherence to lung-protective ventilation strategies are not well known. We describe characteristics and outcomes of confirmed ARDS in COVID-19 patients managed with invasive mechanical ventilation (MV).

Methods: This is a multicenter, prospective, observational study in consecutive, mechanically ventilated patients with ARDS (as defined by the Berlin criteria) affected with with COVID-19 (confirmed SARS-CoV-2 infection in nasal or pharyngeal swab specimens), admitted to a network of 36 Spanish and Andorran intensive care units (ICUs) between March 12 and June 1, 2020. We examined the clinical features, ventilatory management, and clinical outcomes of COVID-19 ARDS patients, and compared some results with other relevant studies in non-COVID-19 ARDS patients.

Results: A total of 742 patients were analysed with complete 28-day outcome data: 128 (17.1%) with mild, 331 (44.6%) with moderate, and 283 (38.1%) with severe ARDS. At baseline, defined as the first day on invasive MV, median (IQR) values were: tidal volume 6.9 (6.3-7.8) ml/kg predicted body weight, positive end-expiratory pressure 12 (11-14) cmH2O. Values of respiratory system compliance 35 (27-45) ml/cmH2O, plateau pressure 25 (22-29) cmH2O, and driving pressure 12 (10-16) cmH2O were similar to values from non-COVID-19 ARDS patients observed in other studies. Recruitment maneuvers, prone position and neuromuscular blocking agents were used in 79%, 76% and 72% of patients, respectively. The risk of 28-day mortality was lower in mild ARDS [hazard ratio (RR) 0.56 (95% CI 0.33-0.93), p = 0.026] and moderate ARDS [hazard ratio (RR) 0.69 (95% CI 0.47-0.97), p = 0.035] when compared to severe ARDS. The 28-day mortality was similar to other observational studies in non-COVID-19 ARDS patients.

Conclusions: In this large series, COVID-19 ARDS patients have features similar to other causes of ARDS, compliance with lung-protective ventilation was high, and the risk of 28-day mortality increased with the degree of ARDS severity.

Trial registration: ClinicalTrials.gov NCT04368975.

Keywords: Acute respiratory distress syndrome; Coronavirus; Mechanical ventilation; Outcome.

Conflict of interest statement

The authors declare no conflicts of interest in relation to this manuscript.

Figures

Fig. 1
Fig. 1
Patients flowchart. A total of 742 patients were followed-up for 28 days and stratified as mild, moderate and severe ARDS based on baseline PaO2/FiO2. ARDS acute respiratory distress syndrome, PaO2/FiO2 partial pressure of arterial oxygen to inspiratory oxygen fraction ration
Fig. 2
Fig. 2
Top panel: daily distribution of patients under invasive mechanical ventilation by ARDS severity (mild, moderate, and severe) from day 1 to 28. Mild: PaO2/FiO2 < 100 mmHg, moderate: PaO2/FiO2 100–200 mmHg, severe: PaO2/FiO2 > 201 and < 300 mmHg. Bottom panel: Daily mean (95% confidence interval) of respiratory system compliance in cmH2O. Only patients under controlled mechanical ventilation are included. ARDS acute respiratory distress syndrome, PaO2/FiO2 partial pressure of arterial oxygen to inspiratory oxygen fraction ration, MV mechanical ventilation
Fig. 3
Fig. 3
Time to event curves using Kaplan–Meier with univariable Cox regression. The probability of discontinuation from mechanical ventilation and the probability of ICU discharge increase with decreasing ARDS. The 28-day probability of death was higher in severe ARDS. ICU intensive care unit, ARDS acute respiratory distress syndrome

References

    1. Wenjie T, Xiang Z, Xuejun M, et al. (2020) A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019−2020. . Accessed 03 July 2020
    1. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020 doi: 10.1001/jama.2020.4031.
    1. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Med. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x.
    1. The COVID-19 Lombardy ICU Network Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574–1581. doi: 10.1001/jama.2020.5394.
    1. Huang C, Yeming W, Xingwang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Gattinoni L, Coppola S, Cressoni M. Covid-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:1299–1300. doi: 10.1164/rccm.202003-0817LE.
    1. Gattinoni L, Chiumello E, Caironi P, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. 2020;46:1099–1102. doi: 10.1007/s00134-020-06033-2.
    1. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 doi: 10.1001/jama.2020.6825.
    1. Ranieri VM, Rubenfeld GD, Thompson BT, ARDS Definition Task Force et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–2533. doi: 10.1001/jama.2012.5669.
    1. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vanderbrouche JP, STROBE Initiative Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–808. doi: 10.1136/.
    1. WHO (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. Published January 25. . Accessed 15 Apr 2020.
    1. Brock GN, Barnes C, Ramirez JA, Myers J. How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Med Res Methodol. 2011;11:144. doi: 10.1186/1471-2288-11-144.
    1. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800. doi: 10.1001/jama.2016.0291.
    1. Kacmarek RM, Villar J, Sulemanji D, Open Lung Approach Network et al. Open lung approach for the acute respiratory distress syndrome: a pilot, randomized controlled trial. Crit Care Med. 2016;44:32–42. doi: 10.1097/CCM.0000000000001383.
    1. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Cavalcanti AB, Suzumura ÉA, et al. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2017;318:1335–1345. doi: 10.1001/jama.2017.14171.
    1. Moss M, Ulysse CA, Angus DC, National Heart, lung and blood institute PETAL clinical trials network Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380:1997–2008. doi: 10.1056/NEJMc1908874.
    1. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–2168. doi: 10.1056/NEJMoa1214103.
    1. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York city. N Engl J Med. 2020;382:2372–2374. doi: 10.1056/NEJMc2010419.
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China. Lancet Respir Med. 2020;S2213–2600(20):30079–30085. doi: 10.1016/S2213-2600(20)30079-5.
    1. Villar J, Blanco J, Añón JM, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med. 2011;37:1932–1941. doi: 10.1007/s00134-011-2380-4.
    1. Madoto F, Pham T, Bellani G, et al. Resolved versus confirmed ARDS after 24h: insights from the LUNG SAFE study. Intensive Care Med. 2018;44:564–577. doi: 10.1007/s00134-018-5152-6.
    1. Villar J, Fernández RL, Ambrós A, et al. A clinical classification on the acute respiratory distress syndrome for predicting outcome and guiding medical therapy. Crit Care Med. 2015;43:346–353. doi: 10.1097/CCM.0000000000000703.
    1. Ziehr DR, Alladina J, Petri CR, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med. 2020;201:1506–1564. doi: 10.1164/rccm.202004-1163LE.
    1. Schenck EJ, Hoffman K, Goyal P, et al. Respiratory mechanics and gas exchange in COVID-19 associated respiratory failure. Ann Am Thorac Soc. 2020 doi: 10.1513/AnnalsATS.202005-427RL.
    1. Bellani G, Pham T, Laffey J. Missed or delayed diagnosis of ARDS: a common and serious problem. Intensive Care Med. 2020;46:1180–1183. doi: 10.1007/s00134-020-06035-0.
    1. Pistillo N, Fariña O. Driving airway and transpulmonary pressure are correlated to VILI determinants during controlled ventilation. Intensive Care Med. 2018;44:674–675. doi: 10.1007/s00134-018-5092-1.
    1. Pensier J, de Jong A, Hajjej Z, et al. Effect of lung recruitment maneuver on oxygenation, physiological parameters and mortality in acute respiratory distress syndrome patients: a systematic review and meta-analysis. Intensive Care Med. 2019;45:1691–1702. doi: 10.1007/s00134-019-05821-9.
    1. Guérin C, Beuret P, Constantin JM, Investigators of the APRONET Study Group, the REVA Network, the Réseau recherche de la Société Française d’Anesthésie-Réanimation (SFAR-recherche) and the ESICM Trials Group et al. A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study. Intensive Care Med. 2018;44:22–37. doi: 10.1007/s00134-017-4996-5.
    1. Beloncle FM, Pavlovsky B, Desprez C, et al. Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome. Ann Intensive Care. 2020;10:55. doi: 10.1186/s13613-020-00675-7.
    1. Spinelli E, Mauri T, Beitler J, et al. Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions. Intensive Care Med. 2020;46:606–618. doi: 10.1007/s00134-020-05942-6.
    1. Slutsky AS, Villar J. Early paralytic agents for ARDS? Yes, no, sometimes. N Engl J Med. 2019;380:2061–2063. doi: 10.1056/NEJMe1905627.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–1614. doi: 10.1001/jama.2020.4326.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅